Logo1

Sychev DA, Baturina OA, Mirzaev KB, Rytkin E, Ivashchenko DV, Andreev DA, Ryzhikova KA, Grishina EA, Bochkov PO, Shevchenko RV
CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban
Pharmacogenomics and Personalized Medicine Volume 2020:13 Pages 29—37

 

скачать материал

Dorofeeva MN, Shikh EV, Sizova ZM, Tarasenko AV, Denisenko NP, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA, Sychev DA
Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects
Pharmgenomics Pers Med. 2019;12:329-339.
 DOI https://doi.org/10.2147/PGPM.S217725

скачать материал

Mirzaev KB, Osipova DV, Kitaeva EJ, Shprakh VV, Abdullaev SP, Andreev DA, Mumladze RB, Sychev DA.
Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel.
Drug Metab Pers Ther. 2019:1-8. Sep 27.
doi: 10.1515/dmpt-2018-0039.

 

скачать материал

Sychev D, Minnigulov R, Bochkov P, Ryzhikova K, Yudina I, Lychagin A, Morozova T.
Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery.
High Blood Press Cardiovasc Prev. 2019 Oct 15.
doi: 10.1007/s40292-019-00342-4.

 

скачать материал

 

Mirzaev KB, Fedorinov DS, Ivashchenko DV, Sychev DA.
ADME pharmacogenetics: future outlook for Russia.
Pharmacogenomics. 2019 Jul;20(11):847-865.

doi: 10.2217/pgs-2019-0013.

 

скачать материал